This Federal Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $959,066 to Jelikalite Corp. to develop a non-invasive medical device and software platform for personalized transcranial photobiomodulation therapy to improve communication, social skills, and independence for children with autism spectrum disorder.
The key products being developed include: 1) a wearable device that delivers targeted photobiomodulation therapy based on integrated electroencephalogram (EEG) measurements, and 2) a software and data platform to evaluate treatment efficacy and personalize the therapy through machine learning. The project aims to finalize the prototype device for clinical adoption and commercialization, as well as enhance the understanding of autism mechanisms through data aggregation. This award supports the small business's efforts to create a novel, evidence-based treatment to address the unmet needs and high costs associated with autism spectrum disorder.
Generated 3/4/25, 6:25 AM